WHOOP drops the membership requirement for lab testing — and adds Galleri

August 19, 2026 · Platform news · WHOOP · Quest Diagnostics · Galleri (GRAIL)

What happened

In a joint announcement dated Boston, August 18, 2026, WHOOP and Quest Diagnostics said WHOOP Advanced Labs is now available without a WHOOP membership for the first time, and that GRAIL's Galleri multi-cancer early detection test has been added to the Advanced Labs portfolio. Per the announcement, Advanced Labs is powered in the U.S. by Quest and delivers results across cardiovascular, metabolic, hormonal and inflammatory panels with clinician review, while Galleri is offered through a single blood draw at nearly 2,000 Quest locations and screens for a signal associated with more than 50 types of cancer. WHOOP states that testing through Advanced Labs "starts at approximately $150."

What it means for you

Until now, a reader comparing platforms did not really weigh WHOOP against a blood-testing membership, because the two answered different questions and one of them required buying hardware and a subscription first. Removing the membership gate removes that separation. Someone who wants a comprehensive panel with clinician-reviewed results and an app to read them in now has one more route to it, and the route runs through a national lab network rather than a startup's own draw sites. If physical access to a draw has been the friction in your decision, that is the part of this that actually helps you.

Treat the entry price carefully. "Starts at approximately $150" is a floor, not a panel price, and the announcement does not say what marker coverage that tier buys or what the specialized panels cost on top of it. The same release sets that figure against a stated figure of more than $3,000 for comparable comprehensive assessments in traditional healthcare settings — a company's own framing of its own value, and not a like-for-like benchmark against the membership platforms on our platform hub. The comparison that matters is narrower and duller: which markers, how often, reviewed by whom, and what a repeat test costs in month seven. Our Function Health review and InsideTracker review lay out those same four columns for the incumbents, and the price on any of them should be checked against the vendor's live page before you buy, including this one.

On Galleri, separate the shelf from the science. Selling a test inside a consumer fitness app widens who encounters it, and it does not move the evidence an inch. GRAIL's own site states the test has not been cleared or approved by the FDA, that it is a laboratory developed test whose performance characteristics GRAIL itself determined, and that it is prescription-only. GRAIL further states it is recommended for adults with an elevated risk for cancer, such as those aged 50 or older, that it does not detect all cancers, and that it should be used in addition to routine screening a healthcare provider recommends. Those sentences come from the manufacturer, not from a critic, and they are the frame a buyer should read the app-store version through. The FDA advisory committee scheduled to review Galleri's premarket approval application on September 23, 2026 — covered in our earlier briefing — is still ahead, not behind.

How this fits what we already know

Our WHOOP review has always assessed it as a recovery and strain wearable, judged on sensor accuracy and what its scores are good for. This announcement puts the same company in the category our platform lineup covers, on the axis those platforms actually compete on: panel breadth, clinician review, cadence and total cost. Meanwhile Galleri keeps its own distinctive position — the only blood-based multi-cancer screen among the platforms we benchmark, with the widest gap between what it can detect and what has been proven to change outcomes. Adding a consumer distribution channel does not narrow that gap. We will reassess both pages on their own review cycles as the pricing and panel details of the non-member tier become verifiable on WHOOP's own pages.

Sources

• WHOOP and Quest Diagnostics, "WHOOP Makes Advanced Labs Available Without a Wearable" (Boston, August 18, 2026), press release as reproduced at stocktitan.net (accessed August 19, 2026).
• GRAIL, Galleri official site and important safety information, galleri.com (accessed August 19, 2026).
• Fierce Healthcare, "Whoop expands advanced labs offering to non-members, adds Grail's multi-cancer detection test," fiercehealthcare.com (headline and framing only; full text not retrievable, August 19, 2026).